Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Alzheimer's Disease

Free Subscription Articles published in Ann Neurol Retrieve available abstracts of 83 articles: HTML format

Single Articles

September 2026
1. LIM S, Lee Y, Yun CS, Kim K, et al
   Change in Amyloid-beta Deposition and Diffusion Tensor Image Analysis along the Perivascular Space Index in Incident Neurodegenerative Disease.
   Ann Neurol. 2026;100:559-571.
   PubMed     Abstract available
   
   
   August 2026
2. SUDHOF TC
   Challenges in Studying Synapses in Alzheimer's Disease.
   Ann Neurol. 2026 Aug 20. doi: 10.1002/ana.78331.
   PubMed     Abstract available
   
   
   
3. JIANG M, Lan G, Zhu J, Zhang L, et al
   Cross-Sectional and Longitudinal Diagnostic Performance of Plasma p-tau217 and p-tau217/Abeta42 in Alzheimer's Disease.
   Ann Neurol. 2026 Aug 14. doi: 10.1002/ana.78322.
   PubMed     Abstract available
   
   
   
4. PENA-TAUBER A, Hernandez Arriaza R, Reil D, Muntaner M, et al
   Genetic Modifiers of ABCA1 Activity Interact with APOE Isoforms to Mediate Alzheimer's Disease Risk.
   Ann Neurol. 2026 Aug 3. doi: 10.1002/ana.78303.
   PubMed     Abstract available
   
   
   July 2026
5. VALLETTA M, Vetrano DL, Laukka EJ, Kalpouzos G, et al
   Blood Biomarkers of Alzheimer's Disease and Patterns of Structural Brain Changes in the Community.
   Ann Neurol. 2026 Jul 27. doi: 10.1002/ana.78309.
   PubMed     Abstract available
   
   
   May 2026
6. KASPER E, Lehto A, Jurs A, Nordmann N, et al
   Alzheimer's Disease Co-Pathology and Cognitive Impairment in Amyotrophic Lateral Sclerosis.
   Ann Neurol. 2026 May 11. doi: 10.1002/ana.78227.
   PubMed     Abstract available
   
   
   
7. JIANG X, O'Bryant SE, Rissman RA, Johnson LA, et al
   Multimorbidity and Associations with Cognition and Alzheimer's Disease Biomarkers.
   Ann Neurol. 2026 May 4. doi: 10.1002/ana.78238.
   PubMed     Abstract available
   
   
   April 2026
8. YOUSSEF H, Gatto RG, Ghayal NB, Estades Ayuso V, et al
   Biochemical and Immunohistochemical Associations of TDP-43 and Cryptic RNA With Hippocampal and Amygdala Volumetrics in Alzheimer's Disease.
   Ann Neurol. 2026 Apr 8. doi: 10.1002/ana.78223.
   PubMed     Abstract available
   
   
   March 2026
9. TROPEA TF, Stevenson PA, Flitter M, Meehan D, et al
   Association between Plasma P-tau217 and Alzheimer's Copathology and Cognitive Decline in Parkinson's Disease.
   Ann Neurol. 2026 Mar 18. doi: 10.1002/ana.78201.
   PubMed     Abstract available
   
   
   
10. XU YR, Tao Y, Lish AM, Li S, et al
    Novel Monoclonal Antibody Detects Small Abeta Oligomers More Sensitively Than Lecanemab in Alzheimer's Disease CSF, Serum and Culture Media.
    Ann Neurol. 2026 Mar 16. doi: 10.1002/ana.78196.
    PubMed     Abstract available
    
    
    
11. BROWN CA, Cousins KAQ, Korecka M, McGrew E, et al
    Temporal Modeling of Amyloid and Tau Trajectories in Alzheimer's Disease Using PET and Plasma Biomarkers.
    Ann Neurol. 2026 Mar 15. doi: 10.1002/ana.78194.
    PubMed     Abstract available
    
    
    
12. IBANEZ L, Pottier C, Beric A, Western D, et al
    Understanding Neurodegenerative Diseases From the -Omics Perspective: Lessons Learnt.
    Ann Neurol. 2026;99:566-587.
    PubMed     Abstract available
    
    
    February 2026
13. B SZABO A, Curot J, Gerard F, Rulquin F, et al
    Refining Detection of Subclinical Epileptiform Activity in Alzheimer's Disease: A Case-Control Study and Call for a Consensus.
    Ann Neurol. 2026 Feb 11. doi: 10.1002/ana.78135.
    PubMed     Abstract available
    
    
    January 2026
14. CANOVAS R, Cox T, Dore V, Bourgeat P, et al
    When Does Alzheimer's Disease Start? Plasma Abeta42/40 Assays Show Steep Changes at Abeta-PET Centiloid 15, Mean Age of 66 Years.
    Ann Neurol. 2026 Jan 26. doi: 10.1002/ana.78163.
    PubMed     Abstract available
    
    
    
15. MABOUDIAN SA, Fonseca CS, Martersteck AC, Chao Y, et al
    Tau Pathology in Alzheimer's Disease Uniquely Affects Sulcal Depths.
    Ann Neurol. 2026 Jan 24. doi: 10.1002/ana.78166.
    PubMed     Abstract available
    
    
    December 2025
16. COUSINS KAQ, Boyle R, Morse C, Verma A, et al
    Electronic Health Records to Test Multimorbidity Influences to Plasma Biomarker Interpretation for Alzheimer's Disease.
    Ann Neurol. 2025 Dec 25. doi: 10.1002/ana.78114.
    PubMed     Abstract available
    
    
    October 2025
17. PIURA YD, Satyadev N, Corriveau-Lecavalier N, Kuchenbecker LA, et al
    Decoding the Clinical Features that Associate with Progression, Causes, and Outcomes in Patients with Suspected Rapidly Progressive Dementia.
    Ann Neurol. 2025;98:764-776.
    PubMed     Abstract available
    
    
    September 2025
18. ABDELMOITY O, Wisch JK, Kennedy JT, Goyal M, et al
    Cross-Sectional FDG in Down Syndrome and Autosomal Dominant Alzheimer's Disease.
    Ann Neurol. 2025 Sep 22. doi: 10.1002/ana.78002.
    PubMed     Abstract available
    
    
    
19. GRAFF-RADFORD J, Syrjanen JA, Vemuri P, Lowe VJ, et al
    Predictive Value of Plasma Biomarkers in Tau-PET Transitions.
    Ann Neurol. 2025 Sep 10. doi: 10.1002/ana.78003.
    PubMed     Abstract available
    
    
    
20. BUCKLEY RF, Scott M, McGrath ER, Coughlan G, et al
    Midlife Steroid-Binding Globulin Levels and In Vivo Neuroimaging Measures of Tau in Older Men and Women.
    Ann Neurol. 2025;98:524-532.
    PubMed     Abstract available
    
    
    July 2025
21. GUNASEKARAN TI, Sanchez D, Reyes-Dumeyer D, Ventura R, et al
    Frequency of Microvascular Pathology and Hippocampal Atrophy on Magnetic Resonance Imaging in a Community Study of Alzheimer's Disease with Blood-Based Biomarkers.
    Ann Neurol. 2025 Jul 30. doi: 10.1002/ana.70006.
    PubMed     Abstract available
    
    
    
22. WOOD ALEXANDER M, Fischer DL, VandeVrede L, Nichols E, et al
    Sex Differences in Associations of Lewy Body Disease with Alzheimer's Disease and Cognitive Decline.
    Ann Neurol. 2025 Jul 11. doi: 10.1002/ana.27308.
    PubMed     Abstract available
    
    
    June 2025
23. MILA-ALOMA M, Tosun D, Schindler SE, Hausle I, et al
    Timing of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau PET Clocks.
    Ann Neurol. 2025 Jun 20. doi: 10.1002/ana.27285.
    PubMed     Abstract available
    
    
    
24. REYES A, Zawar I, Punia V, Sarkis RA, et al
    Clinical and Cognitive Profiles of Individuals with Alzheimer's Disease and Comorbid Seizures.
    Ann Neurol. 2025 Jun 16. doi: 10.1002/ana.27284.
    PubMed     Abstract available
    
    
    April 2025
25. AFFANEH A, Linden AK, Tunc-Ozcan E, Tsai YH, et al
    Inhibition of Bone Morphogenetic Protein Signaling Prevents Tau Pathology in iPSC Derived Neurons and PS19 Mice.
    Ann Neurol. 2025;97:657-672.
    PubMed     Abstract available
    
    
    March 2025
26. LAGARDE J, Maiti P, Schonhaut DR, Blazhenets G, et al
    Amyloid PET in Sporadic Early- Versus Late-Onset Alzheimer's Disease: Comparison of the LEADS and ADNI Cohorts.
    Ann Neurol. 2025 Mar 17. doi: 10.1002/ana.27233.
    PubMed     Abstract available
    
    
    
27. ARRIOLA-INFANTE JE, Morcillo-Nieto AO, Zsadanyi SE, Franquesa-Mullerat M, et al
    Regional Brain Metabolism across the Alzheimer's Disease Continuum in Down Syndrome.
    Ann Neurol. 2025 Mar 14. doi: 10.1002/ana.27226.
    PubMed     Abstract available
    
    
    February 2025
28. KEUM M, Byun MS, Yi D, Ahn H, et al
    The Use of Antihypertensive Medication and In Vivo Alzheimer's Disease Pathology.
    Ann Neurol. 2025 Feb 17. doi: 10.1002/ana.27204.
    PubMed     Abstract available
    
    
    January 2025
29. WILLIAMS ME, Fennema-Notestine C, Bell TR, Lin SJ, et al
    Neuroimaging Predictors of Cognitive Resilience against Alzheimer's Disease Pathology.
    Ann Neurol. 2025 Jan 31. doi: 10.1002/ana.27186.
    PubMed     Abstract available
    
    
    
30. NOGUCHI-SHINOHARA M, Shuta K, Murakami H, Mori Y, et al
    Lecanemab-Associated Amyloid-beta Protofibril in Cerebrospinal Fluid Correlates with Biomarkers of Neurodegeneration in Alzheimer's Disease.
    Ann Neurol. 2025 Jan 6. doi: 10.1002/ana.27175.
    PubMed     Abstract available
    
    
    October 2024
31. YUAN J, Tao Q, Ang TFA, Liu C, et al
    The Relationship between Framingham Stroke Risk Profile on Incident Dementia and Alzheimer's Disease: A 40-Year Follow-Up Study Highlighting Female Vulnerability.
    Ann Neurol. 2024 Oct 15. doi: 10.1002/ana.27108.
    PubMed     Abstract available
    
    
    September 2024
32. ABDELNOUR C, Young CB, Shahid-Besanti M, Smith A, et al
    Plasma pTau181 Reveals a Pathological Signature that Predicts Cognitive Outcomes in Lewy Body Disease.
    Ann Neurol. 2024;96:526-538.
    PubMed     Abstract available
    
    
    
33. CHEN C, Lan Z, Tang X, Chen W, et al
    Human-Derived Induced GABAergic Progenitor Cells Improve Cognitive Function in Mice and Inhibit Astrocyte Activation with Anti-Inflammatory Exosomes.
    Ann Neurol. 2024;96:488-507.
    PubMed     Abstract available
    
    
    August 2024
34. MASURKAR AV, Marsh K, Morgan B, Leitner D, et al
    Factors Affecting Resilience and Prevention of Alzheimer's Disease and Related Dementias.
    Ann Neurol. 2024 Aug 17. doi: 10.1002/ana.27055.
    PubMed     Abstract available
    
    
    July 2024
35. BRIER MR, Schindler SE, Salter A, Perantie D, et al
    Unexpected Low Rate of Amyloid-beta Pathology in Multiple Sclerosis Patients.
    Ann Neurol. 2024 Jul 4. doi: 10.1002/ana.27027.
    PubMed     Abstract available
    
    
    June 2024
36. LAH JJ, Tian G, Risk BB, Hanfelt JJ, et al
    Lower Prevalence of Asymptomatic Alzheimer's Disease Among Healthy African Americans.
    Ann Neurol. 2024 Jun 25. doi: 10.1002/ana.26960.
    PubMed     Abstract available
    
    
    
37. SOLEIMANI-MEIGOONI DN, Smith R, Provost K, Lesman-Segev OH, et al
    Head-to-Head Comparison of Tau and Amyloid Positron Emission Tomography Visual Reads for Differential Diagnosis of Neurodegenerative Disorders: An International, Multicenter Study.
    Ann Neurol. 2024 Jun 18. doi: 10.1002/ana.27008.
    PubMed     Abstract available
    
    
    
38. KANAZAWA T, Sato W, Raveney BJE, Takewaki D, et al
    Pathogenic Potential of Eomesodermin-Expressing T-Helper Cells in Neurodegenerative Diseases.
    Ann Neurol. 2024;95:1093-1098.
    PubMed     Abstract available
    
    
    May 2024
39. DICARLO M, Pignataro P, Zecca C, Dell'Abate MT, et al
    Irisin Levels in Cerebrospinal Fluid Correlate with Biomarkers and Clinical Dementia Scores in Alzheimer Disease.
    Ann Neurol. 2024 May 23. doi: 10.1002/ana.26946.
    PubMed     Abstract available
    
    
    
40. CHEN XQ, Becker A, Albay R, Nguyen PD, et al
    gamma-Secretase Modulator BPN15606 Reduced Abeta42 and Abeta40 and Countered Alzheimer-Related Pathologies in a Mouse Model of Down Syndrome.
    Ann Neurol. 2024 May 15. doi: 10.1002/ana.26958.
    PubMed     Abstract available
    
    
    
41. HARRISON TM, Chadwick T, Pezzoli S, Lee J, et al
    Cognitive Trajectories and Alzheimer Disease Biomarkers: From Successful Cognitive Aging to Clinical Impairment.
    Ann Neurol. 2024 May 15. doi: 10.1002/ana.26964.
    PubMed     Abstract available
    
    
    
42. LAN G, Chen X, Yang J, Sun P, et al
    Microglial Reactivity Correlates with Presynaptic Loss Independent of beta-Amyloid and Tau.
    Ann Neurol. 2024;95:917-928.
    PubMed     Abstract available
    
    
    April 2024
43. GARCIA-CORDERO I, Anastassiadis C, Khoja A, Morales-Rivero A, et al
    Evaluating the Effect of Alzheimer's Disease-Related Biomarker Change in Corticobasal Syndrome and Progressive Supranuclear Palsy.
    Ann Neurol. 2024 Apr 5. doi: 10.1002/ana.26930.
    PubMed     Abstract available
    
    
    
44. SAKOWSKI SA, Koubek EJ, Chen KS, Goutman SA, et al
    Role of the Exposome in Neurodegenerative Disease: Recent Insights and Future Directions.
    Ann Neurol. 2024;95:635-652.
    PubMed     Abstract available
    
    
    
45. ARVANITAKIS Z, Capuano AW, Tong H, Mehta RI, et al
    Associations of Serum Insulin and Related Measures With Neuropathology and Cognition in Older Persons With and Without Diabetes.
    Ann Neurol. 2024;95:665-676.
    PubMed     Abstract available
    
    
    March 2024
46. 
    Retraction: 5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of alzheimer disease.
    Ann Neurol. 2024 Mar 28. doi: 10.1002/ana.26938.
    PubMed     Abstract available
    
    
    
47. PALPATZIS E, Akinci M, Aguilar-Dominguez P, Garcia-Prat M, et al
    Lifetime Stressful Events Associated with Alzheimer's Pathologies, Neuroinflammation and Brain Structure in a Risk Enriched Cohort.
    Ann Neurol. 2024 Mar 11. doi: 10.1002/ana.26881.
    PubMed     Abstract available
    
    
    
48. LACHNER C, Craver EC, Babulal GM, Lucas JA, et al
    Disparate Dementia Risk Factors Are Associated with Cognitive Impairment and Rates of Decline in African Americans.
    Ann Neurol. 2024;95:518-529.
    PubMed     Abstract available
    
    
    
49. PAPP KV, Jutten RJ, Soberanes D, Weizenbaum E, et al
    Early Detection of Amyloid-Related Changes in Memory among Cognitively Unimpaired Older Adults with Daily Digital Testing.
    Ann Neurol. 2024;95:507-517.
    PubMed     Abstract available
    
    
    February 2024
50. VAN EGROO M, van Someren EJW, Grinberg LT, Bennett DA, et al
    Associations of 24-Hour Rest-Activity Rhythm Fragmentation, Cognitive Decline, and Postmortem Locus Coeruleus Hypopigmentation in Alzheimer's Disease.
    Ann Neurol. 2024 Feb 26. doi: 10.1002/ana.26880.
    PubMed     Abstract available
    
    
    
51. LI Y, Yen D, Hendrix RD, Gordon BA, et al
    Timing of Biomarker Changes in Sporadic Alzheimer's Disease in Estimated Years from Symptom Onset.
    Ann Neurol. 2024 Feb 24. doi: 10.1002/ana.26891.
    PubMed     Abstract available
    
    
    
52. PHAN TX, Baratono S, Drew W, Tetreault AM, et al
    Increased Cortical Thickness in Alzheimer's Disease.
    Ann Neurol. 2024 Feb 24. doi: 10.1002/ana.26894.
    PubMed     Abstract available
    
    
    
53. SALTIEL N, Tripodis Y, Menzin T, Olaniyan A, et al
    Relative Contributions of Mixed Pathologies to Cognitive and Functional Symptoms in Brain Donors Exposed to Repetitive Head Impacts.
    Ann Neurol. 2024;95:314-324.
    PubMed     Abstract available
    
    
    
54. KUCHENBECKER LA, Tipton PW, Martens Y, Brier MR, et al
    Diagnostic Utility of Cerebrospinal Fluid Biomarkers in Patients with Rapidly Progressive Dementia.
    Ann Neurol. 2024;95:299-313.
    PubMed     Abstract available
    
    
    
55. CHEN X, Toueg TN, Harrison TM, Baker SL, et al
    Regional Tau Deposition Reflects Different Pathways of Subsequent Neurodegeneration and Memory Decline in Cognitively Normal Older Adults.
    Ann Neurol. 2024;95:249-259.
    PubMed     Abstract available
    
    
    January 2024
56. VANCE JM, Farrer LA, Huang Y, Cruchaga C, et al
    Report of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer's Disease.
    Ann Neurol. 2024 Jan 5. doi: 10.1002/ana.26864.
    PubMed     Abstract available
    
    
    December 2023
57. BONOMI S, Lu R, Schindler SE, Bui Q, et al
    Relationships of Cognitive Measures with Cerebrospinal Fluid but not Imaging Biomarkers of Alzheimer Disease Vary between Black and White Individuals.
    Ann Neurol. 2023 Dec 1. doi: 10.1002/ana.26838.
    PubMed     Abstract available
    
    
    October 2023
58. ZHENG L, Rubinski A, Dennecke J, Luan Y, et al
    Combined Connectomics, MAPT Gene Expression, and Amyloid Deposition to Explain Regional Tau Deposition in Alzheimer's Disease.
    Ann Neurol. 2023 Oct 14. doi: 10.1002/ana.26818.
    PubMed     Abstract available
    
    
    
59. GRILL JD, Flournoy C, Dhadda S, Ernstrom K, et al
    Eligibility rates among racially and ethnically diverse US participants in Phase 2 and Phase 3 placebo-controlled, double-blind, randomized trials of lecanemab and elenbecestat in early Alzheimer's disease.
    Ann Neurol. 2023 Oct 13. doi: 10.1002/ana.26819.
    PubMed     Abstract available
    
    
    
60. DARK HE, Paterson C, Daya GN, Peng Z, et al
    Proteomic indicators of health predict Alzheimer's disease biomarker levels and dementia risk.
    Ann Neurol. 2023 Oct 6. doi: 10.1002/ana.26817.
    PubMed     Abstract available
    
    
    
61. SHAW LM, Galasko D
    Assessments of the Utilities of CSF NPTX2 for Disease Progression in Cognitively Normal Individuals Who Progress to Clinical MCI and AD.
    Ann Neurol. 2023;94:618-619.
    PubMed    
    
    
    
62. SOLDAN A, Oh S, Ryu T, Pettigrew C, et al
    NPTX2 in Cerebrospinal Fluid Predicts the Progression From Normal Cognition to Mild Cognitive Impairment.
    Ann Neurol. 2023;94:620-631.
    PubMed     Abstract available
    
    
    September 2023
63. HIRATA K, Matsuoka K, Tagai K, Endo H, et al
    Altered brain energy metabolism related to astrocytes in Alzheimer's disease.
    Ann Neurol. 2023 Sep 13. doi: 10.1002/ana.26797.
    PubMed     Abstract available
    
    
    August 2023
64. MINOGUE G, Kawles A, Zouridakis A, Keszycki R, et al
    Distinct Patterns of Hippocampal Pathology in Alzheimer's Disease with TDP-43.
    Ann Neurol. 2023 Aug 18. doi: 10.1002/ana.26762.
    PubMed     Abstract available
    
    
    
65. KOSIK KS
    Search Strategies for Alzheimer Protector Genes.
    Ann Neurol. 2023 Aug 13. doi: 10.1002/ana.26764.
    PubMed     Abstract available
    
    
    
66. YU L, Petyuk VA, Lopes KP, Tasaki S, et al
    Associations of VGF with Neuropathologies and Cognitive Health in Older Adults.
    Ann Neurol. 2023;94:232-244.
    PubMed     Abstract available
    
    
    
67. CHEN XQ, Sawa M, Becker A, Karachentsev D, et al
    Retromer Proteins Reduced in Down Syndrome and the Dp16 Model: Impact of APP Dose and Preclinical Studies of a gamma-Secretase Modulator.
    Ann Neurol. 2023;94:245-258.
    PubMed     Abstract available
    
    
    July 2023
68. KUHLENBAUMER G, Jensen-Kondering U, Margraf NG
    Decreased Cerebrospinal Fluid Amyloid Beta 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy.
    Ann Neurol. 2023;94:205.
    PubMed    
    
    
    
69. LUCEY BP, Liu H, Toedebusch CD, Freund D, et al
    Suvorexant Acutely Decreases Tau Phosphorylation and Abeta in the Human CNS.
    Ann Neurol. 2023;94:27-40.
    PubMed     Abstract available
    
    
    June 2023
70. LUCEY BP, Bateman RJ
    Reply to Suvorexant for preventing Alzheimer's disease.
    Ann Neurol. 2023 Jun 28. doi: 10.1002/ana.26728.
    PubMed    
    
    
    
71. KAWADA T
    Suvorexant for preventing Alzheimer's disease.
    Ann Neurol. 2023 Jun 27. doi: 10.1002/ana.26733.
    PubMed    
    
    
    
72. DE KORT AM, Kuiperij HB, Marques TM, Jakel L, et al
    Decreased Cerebrospinal Fluid Amyloid beta 38, 40, 42, and 43 Levels in Sporadic and Hereditary Cerebral Amyloid Angiopathy.
    Ann Neurol. 2023;93:1173-1186.
    PubMed     Abstract available
    
    
    May 2023
73. NELSON PT, Schneider JA, Jicha GA, Duong MT, et al
    When Alzheimer's is LATE: Why does it matter?
    Ann Neurol. 2023 May 28. doi: 10.1002/ana.26711.
    PubMed     Abstract available
    
    
    
74. HOOSHMAND B, Appold F, Fissler P, Perneczky R, et al
    Markers of vitamin B12 status in relation to cerebrospinal fluid biomarkers of Alzheimer's disease and cognitive performance.
    Ann Neurol. 2023 May 12. doi: 10.1002/ana.26673.
    PubMed     Abstract available
    
    
    
75. ANDRE C, Champetier P, Rehel S, Kuhn E, et al
    Rapid Eye Movement Sleep, Neurodegeneration, and Amyloid Deposition in Aging.
    Ann Neurol. 2023;93:979-990.
    PubMed     Abstract available
    
    
    April 2023
76. NEDELEC T, Couvy-Duchesne B, Darves-Bornoz A, Couronne R, et al
    A comparison between early presentation of dementia with Lewy Bodies, Alzheimer's disease and Parkinson's disease: evidence from routine primary care and UK Biobank data.
    Ann Neurol. 2023 Apr 25. doi: 10.1002/ana.26670.
    PubMed     Abstract available
    
    
    
77. SHAHID M, Rawls A, Ramirez V, Ryman S, et al
    Illusory Responses across the Lewy Body Disease Spectrum.
    Ann Neurol. 2023;93:702-714.
    PubMed     Abstract available
    
    
    March 2023
78. MUSIEK ES, McDade E, Holtzman DM
    Lecanamab ushers in a new era of anti-amyloid therapy for Alzheimer's Disease.
    Ann Neurol. 2023 Mar 15. doi: 10.1002/ana.26643.
    PubMed    
    
    
    
79. PYUN JM, Park YH, Wang J, Bice PJ, et al
    Aberrant GAP43 gene expression is Alzheimer's disease pathology-specific.
    Ann Neurol. 2023 Mar 10. doi: 10.1002/ana.26637.
    PubMed    
    
    
    
80. LAN G, Guo T
    Reply to: "Aberrant GAP43 gene expression is Alzheimer's disease pathology-specific".
    Ann Neurol. 2023 Mar 10. doi: 10.1002/ana.26639.
    PubMed    
    
    
    
81. TROPEA TF, Albuja I, Cousins KAQ, Irwin DJ, et al
    Concomitant Alzheimer's Disease Pathology in Parkinson's Disease Dementia.
    Ann Neurol. 2023 Mar 9. doi: 10.1002/ana.26635.
    PubMed    
    
    
    
82. YOUNCE JR, Martin WRW, Perlmutter JS
    Reply to "Concomitant Alzheimer's Disease Pathology in Parkinson's Disease Dementia".
    Ann Neurol. 2023 Mar 9. doi: 10.1002/ana.26630.
    PubMed    
    
    
    February 2023
83. HORIE K, Li Y, Barthelemy NR, Gordon BA, et al
    Change in cerebrospinal fluid tau microtubule binding region detects symptom onset, cognitive decline, tangles, and atrophy in Dominantly Inherited Alzheimer's Disease.
    Ann Neurol. 2023 Feb 26. doi: 10.1002/ana.26620.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum